CO2020006648A2 - Derivados de imidazopiridina y su uso como medicamento - Google Patents

Derivados de imidazopiridina y su uso como medicamento

Info

Publication number
CO2020006648A2
CO2020006648A2 CONC2020/0006648A CO2020006648A CO2020006648A2 CO 2020006648 A2 CO2020006648 A2 CO 2020006648A2 CO 2020006648 A CO2020006648 A CO 2020006648A CO 2020006648 A2 CO2020006648 A2 CO 2020006648A2
Authority
CO
Colombia
Prior art keywords
medicine
imidazopyridine derivatives
nr2b
treatments
prevention
Prior art date
Application number
CONC2020/0006648A
Other languages
English (en)
Inventor
Riccardo Giovannini
Angelo Ceci
Georg Dahmann
Cornelia Dorner-Ciossek
Lothar Kussmaul
Roland Pfau
Dieter Wiedenmayer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO2020006648A2 publication Critical patent/CO2020006648A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención se refiere a imidazopiridinas novedosas de la Fórmula A A, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en tratamientos, particularmente, en el tratamiento o prevención de afecciones que tienen una relación con las propiedades de modulación alostérica negativa de NR2B.
CONC2020/0006648A 2017-12-08 2020-05-29 Derivados de imidazopiridina y su uso como medicamento CO2020006648A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17206152 2017-12-08
PCT/EP2018/083728 WO2019110703A1 (en) 2017-12-08 2018-12-06 Imidazopyridine derivatives and the use thereof as medicament

Publications (1)

Publication Number Publication Date
CO2020006648A2 true CO2020006648A2 (es) 2020-06-09

Family

ID=60629568

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0006648A CO2020006648A2 (es) 2017-12-08 2020-05-29 Derivados de imidazopiridina y su uso como medicamento

Country Status (31)

Country Link
US (1) US10849907B2 (es)
EP (1) EP3720855B1 (es)
JP (1) JP6941235B2 (es)
KR (1) KR20200097301A (es)
CN (1) CN111344291B (es)
AR (1) AR113923A1 (es)
AU (1) AU2018379438B2 (es)
BR (1) BR112020008583A2 (es)
CA (1) CA3083331A1 (es)
CL (1) CL2020001402A1 (es)
CO (1) CO2020006648A2 (es)
CY (1) CY1124744T1 (es)
DK (1) DK3720855T3 (es)
EA (1) EA202091139A1 (es)
ES (1) ES2897050T3 (es)
HR (1) HRP20211726T1 (es)
HU (1) HUE056667T2 (es)
IL (1) IL274868B1 (es)
LT (1) LT3720855T (es)
MA (1) MA51020B1 (es)
MX (1) MX2020005869A (es)
PE (1) PE20211454A1 (es)
PL (1) PL3720855T3 (es)
PT (1) PT3720855T (es)
RS (1) RS62517B1 (es)
SA (1) SA520412155B1 (es)
SG (1) SG11202005138TA (es)
SI (1) SI3720855T1 (es)
TW (1) TWI809014B (es)
UA (1) UA126247C2 (es)
WO (1) WO2019110703A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3980420B1 (en) * 2019-06-04 2023-04-19 Boehringer Ingelheim International GmbH Imidazopyrazine derivatives and the use thereof as medicament
TW202112378A (zh) 2019-06-04 2021-04-01 德商百靈佳殷格翰國際股份有限公司 嘌呤衍生物及其作為藥物之用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495561B2 (en) * 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
SI1409477T1 (sl) 2001-07-24 2009-02-28 Richter Gedeon Nyrt Derivati piperidina kot antagonisti nmda-receptorjev
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
EP2909180B1 (en) 2012-10-18 2016-10-05 F. Hoffmann-La Roche AG Ethynyl derivatives as modulators of mglur5 receptor activity
EP3110794A1 (en) 2014-02-27 2017-01-04 Merck Patent GmbH Heterocyclic compounds as nav channel inhibitors and uses thereof
JP2017516836A (ja) * 2014-06-04 2017-06-22 リューゲン ホールディングス （ケイマン） リミテッド Ｎｒ２ｂｎｍｄａ受容体アンタゴニストとしてのジフルオロエチルピリジン誘導体
US10913736B2 (en) * 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
SG11201701853YA (en) * 2014-09-15 2017-04-27 Rugen Holdings Cayman Ltd Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists

Also Published As

Publication number Publication date
HRP20211726T1 (hr) 2022-02-18
JP6941235B2 (ja) 2021-09-29
PT3720855T (pt) 2021-11-03
SI3720855T1 (sl) 2021-12-31
SA520412155B1 (ar) 2022-06-05
AR113923A1 (es) 2020-07-01
JP2021505584A (ja) 2021-02-18
IL274868B1 (en) 2024-02-01
TW201936198A (zh) 2019-09-16
IL274868A (en) 2020-07-30
EP3720855B1 (en) 2021-08-25
MX2020005869A (es) 2020-09-09
LT3720855T (lt) 2021-11-10
US10849907B2 (en) 2020-12-01
UA126247C2 (uk) 2022-09-07
CL2020001402A1 (es) 2020-09-21
CY1124744T1 (el) 2022-07-22
PE20211454A1 (es) 2021-08-05
WO2019110703A1 (en) 2019-06-13
ES2897050T3 (es) 2022-02-28
SG11202005138TA (en) 2020-06-29
TWI809014B (zh) 2023-07-21
AU2018379438A1 (en) 2020-05-07
DK3720855T3 (da) 2021-11-08
HUE056667T2 (hu) 2022-02-28
CN111344291B (zh) 2023-05-05
PL3720855T3 (pl) 2022-01-24
US20190175605A1 (en) 2019-06-13
MA51020A (fr) 2021-05-26
MA51020B1 (fr) 2021-10-29
KR20200097301A (ko) 2020-08-18
CA3083331A1 (en) 2019-06-13
BR112020008583A2 (pt) 2020-10-20
RS62517B1 (sr) 2021-11-30
CN111344291A (zh) 2020-06-26
EP3720855A1 (en) 2020-10-14
EA202091139A1 (ru) 2020-11-23
AU2018379438B2 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
ECSP20040257A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CO2018013978A2 (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CO7350655A2 (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
CR20160006A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
UY35142A (es) Derivados de triazolopirazinas como inhibidores de brd4
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
NI201500096A (es) Compuesto químicos
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CO2020006648A2 (es) Derivados de imidazopiridina y su uso como medicamento
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
CL2021000858A1 (es) Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento